JN.1 COVID-19 Booster Safety Confirmed in Danish Study of More than 1 Million Older Adults
August 13, 2025

Danish adults aged 65 and older at high-risk for serious infection with SARS-CoV-2 showed no increased risk of 29 serious adverse events following vaccination.

Donanemab Maintains Cognitive Benefit 3 Years in Early Alzheimer Disease: Daily Dose
August 13, 2025

Your daily dose of the clinical news you may have missed.

What's the Mood Among Infectious Disease Experts Right Now? We Asked William Schaffner, MD
August 12, 2025

Schaffner describes the mood among his colleagues in infectious disease right now as anxious, perplexed, distressed, and angry. They expect the disruptions and their feelings to continue.

Addressing Pediatric Vaccine Hesitancy: Communication Strategies That Work
August 12, 2025

Effective pediatric vaccine conversations require trust and facts. Family physician Sarah Sams, MD, offers tips for addressing concerns without harming patient relationships.

IV Ketamine NRX-100 Gains FDA Fast Track for Suicidal Depression
August 12, 2025

The FDA Fast Track designation for NRX-100 (IV, preservative-free ketamine) expands by 10-fold the potential treatment population that seriously considers suicide.

Noninvasive Primary Care Screening Identifies Elevated LVEDP in Nearly 40% of High-Risk Patients
August 12, 2025

A new study reveals that noninvasive LVEDP screening can enhance heart failure detection and improve patient outcomes in primary care settings.

Nirsevimab Cuts RSV Risk in Healthy Newborns: Daily Dose
August 12, 2025

Your daily dose of the clinical news you may have missed.

Back-to-School Vaccine Catch-Up: Strategies From a Family Physician
August 11, 2025

From EMR reports to targeted nurse visits, Sarah Sams, MD, outlines practical ways PCPs can catch up pediatric vaccinations before school starts.

Does Intranasal Insulin Reach Critical Brain Areas Linked to Memory and Cognition?
August 11, 2025

Insulin delivered via nasal spray in this first-in-human PET imaging study was observed in 11 key brain areas relevant to cognitive decline, validating a new research avenue.

FDA Accepts Gepotidacin for Priority Review for the Treatment of Uncomplicated Urogenital Gonorrhea
August 11, 2025

FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.